Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
DALLAS, April 13, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in three presentations at the ARVO Annual Meeting, taking place April 23-27, 2023 in New Orleans. The management team will also be present at the conference and available to meet at the Nanoscope Therapeutics booth #1056.
Details for the presentations are as follows:
Abstract Title: MCO-010 intravitreal optogenetic therapy in Stargardt disease. 6-month outcomes from the Phase 2 STARLIGHT trial
Dr. Gonzalez will discuss Nanoscope's 6-month safety and efficacy outcomes from the Phase 2 STARLIGHT trial for Stargardt disease. The outcomes will help inform the future clinical development of MCO-010 optogenetic therapy for vision restoration in Stargardt disease and other retinal degenerative conditions.
Abstract Title: Non-viral Targeted Laser Delivery of Multi-Characteristic Opsin Genes for Treatment of Geographic Atrophy
Dr. Mohanty will detail the Optical Coherence Tomography guided non-viral laser approach that provides efficient, spatially targeted delivery of MCO-020 genes into retinal cells in geographic atrophy areas.
Abstract Title: Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)
Dr. Boyer will discuss Nanoscope's 52-week safety and efficacy outcomes from the Phase 2b RESTORE trial, the Company's most advanced clinical program. Efficacy and safety data from the RESTORE trial will provide evidence on the benefit/risk profile of MCO-010 in retinitis pigmentosa.
About Nanoscope Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-301796295.html
SOURCE Nanoscope Therapeutics